Loren Semones
Adult Health · Houston, TXNPI 1760693576
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,451 of the $13,535 with a category attached, or 77.2%. 17 manufacturers reported payments, led by Abbott at 56.5% of the total. Reporting peaked in 2022 at $5,601 and has fallen 68.4% since, to $1,772 in 2025. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $61.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Cvrx, Inc.$2K
- ZOLL Respicardia, Inc.$2K
- Impulse Dynamics (USA) Inc.$881
- Abiomed$161
- Alnylam Pharmaceuticals Inc.$139
- plus $664 from 11 others
What the payments were for
- Travel & lodging$3,08523%
- Food & beverage$10,45177%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 164 | $7,652 |
| Cvrx, Inc. | 24 | $2,204 |
| ZOLL Respicardia, Inc. | 3 | $1,834 |
| Impulse Dynamics (USA) Inc. | 7 | $881 |
| Abiomed | 2 | $161 |
| Alnylam Pharmaceuticals Inc. | 2 | $139 |
| Actelion Pharmaceuticals US, Inc. | 2 | $124 |
| AstraZeneca | 2 | $112 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $98 |
| Merck | 1 | $83 |
| Bayer | 3 | $77 |
| Boehringer Ingelheim | 3 | $66 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Amgen | 1 | $19 |
| Pfizer | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$1,772
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,700
- CARDIOMEMS$1,454
- Barostim Neo System$1,431
- OPTIMIZER$900
- CardioMEMS HF System$457
- OPTIMIZER SMART SYSTEM$315
- HeartMate 3 Left Ventricular Assist Device$291
- Impella$132
- HeartMate Touch$128
- AMVUTTRA$109
How this compares
$13,535 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 14 | $11,240 |
| EntrestoSacubitril/Valsartan | 14 | $8,300 |
| Torsemide | 32 | $1,011 |
| Potassium Chloride | 33 | $456 |
| Metoprolol Succinate | 31 | $279 |
| Furosemide | 25 | $208 |
| Spironolactone | 29 | $158 |
| Digoxin | 12 | $59 |
| Rosuvastatin Calcium | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $112 | $11,24014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Houston
- Kacey LyonsHouston$20K
- Rosa RancesHouston$17K
- Claressa RosacinaHouston$17K
- Michelle MartinHouston$15K
- Anthony SantosHouston$13K
- Dashawn ThomasHouston$11K
- Zandra RiveraHouston$11K
- Brandy KhodrHouston$10K
- Janice TranHouston$10K
- Ester CerdanHouston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.